Skip to main content
SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD. logo

SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD. — Investor Relations & Filings

Ticker · 688238 ISIN · CNE1000059N9 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 486 across all filing types
Latest filing 2026-06-01 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688238

About SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD.

https://www.obio-tech.com/

SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD. is a specialized Contract Development and Manufacturing Organization (CDMO) focused on the gene and cell therapy (GCT) sector. The company provides end-to-end solutions encompassing vector construction, process development, analytical method development, and large-scale GMP manufacturing. Its service portfolio includes the production of viral vectors such as adeno-associated virus (AAV), lentivirus, adenovirus, and oncolytic viruses, as well as plasmid DNA and cell therapy products. Obio Technology supports clients from early-stage research through clinical trials to commercialization. The company operates advanced facilities designed to meet international regulatory standards, facilitating the development of innovative genetic medicines and advanced therapies for global biopharmaceutical partners.

Recent filings

Filing Released Lang Actions
关于董事会秘书变更及高级管理人员变动的公告
Regulatory Filings
2026-06-01 Chinese
关于修订公司部分治理制度的公告
Regulatory Filings
2026-06-01 Chinese
《上海和元生物技术（集团）股份有限公司信息披露管理制度》（2026年5月修订）
Regulatory Filings
2026-06-01 Chinese
《上海和元生物技术（集团）股份有限公司董事会秘书工作细则》（2026年5月修订）
Regulatory Filings
2026-06-01 Chinese
上海市金茂律师事务所关于上海和元生物技术（集团）股份有限公司2025年年度股东会之法律意见书
Regulatory Filings Classification · 75% confidence The document is a legal opinion letter issued by a law firm regarding the convening procedures, participant qualifications, voting procedures, and legality of resolutions at the company’s 2025 annual shareholders’ meeting. It is not the annual report or a financial statement, nor a simple notice of publication. It is also not a management presentation or proxy solicitation document in the usual sense; rather it is a standalone legal compliance opinion filed with the stock exchange. No specialized category (e.g., audit report, earnings release, proxy statement) matches a legal opinion letter, so it falls into the general “Regulatory Filings” (RNS) catch‐all category.
2026-05-13 Chinese
2025年年度股东会会议资料
AGM Information Classification · 100% confidence The document is titled '2025年年度股东会会议资料' which translates to '2025 Annual General Meeting (AGM) Meeting Materials'. It contains detailed agenda, proposals, voting procedures, and reports related to the 2025 Annual General Meeting of Shanghai Obio Technology (Group) Corp., Ltd. The content includes meeting notices, agenda items, board reports, profit distribution proposals, remuneration proposals, and other materials typically shared with shareholders for an AGM. The document is lengthy (15,000 characters) and contains the full meeting materials, not just an announcement or a brief summary. Therefore, it fits the category of AGM Information (AGM-R).
2026-05-07 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.